Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 2, 2006, Pages 99-111

  Siker, Malika L ^a   Chakravarti, Arnab ^b   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anaplastic glioma; Astrocytoma; Chemoradiotherapy; Chemotherapy; Oligoastrocytoma; Oligodendroglioma; Radiotherapy; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; AG 014699; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; CILENGITIDE; DOCETAXEL; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GADOLINIUM TEXAPHYRIN; GEFITINIB; GUANINE DERIVATIVE; LIVER ENZYME; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VATALANIB; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANAPLASTIC CARCINOMA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; CONFUSION; EXCISION REPAIR; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; INSOMNIA; MISMATCH REPAIR; NONHUMAN; PROTEIN DEFICIENCY; REVIEW; SALVAGE THERAPY; STANDARD; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; OLIGODENDROGLIOMA; SALVAGE THERAPY; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33750339323     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.04.005     Document Type: Review

References (93)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics 2005. CA Cancer J Clin 55 (2005) 10-30
2. World Health Organization Classification of Tumors: pathology and genetics: tumors of the nervous system. In: Kleihues P, Cavenee WB, editors. Lyon, France: IARC Press; 2000.
3. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
4. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
6. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23 (2005) 2372-2377
7. Levin V.A., Silver P., Hannigan J., et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18 (1990) 321-324
8. Prados M.D., Scott C., Curran W.J., Nelson D.F., Leibel S., and Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17 (1999) 3389-3395
9. The Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19 (2001) 509-518
10. Levin V.A., Hess K.R., Choucair A., et al. Phase III randomized study of postradiotherapy chemotherapy with combination a-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Can Res 9 (2003) 981-990
11. Yung W.K., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol 17 (1999) 2762-2771
12. Cairncross J.G., and Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23 (1988) 360-364
13. Kim L., Hochberg F.H., Thornton A.F., et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85 (1996) 602-607
14. Cairncross G, Seiferheld W, Shaw E, et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. J Clin Oncol 2004 [ASCO Annual Meeting Proceedings]; 22(14S):1500.
15. van den Bent MJ, Delattre J, Brandes AA, et al. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. J Clin Oncol 2005 [ASCO Annual Meeting Proceedings]; 23(16S):1503.
16. Wedge S.R., Porteous J.K., Glaser M.G., Marcus K., and Newlands E.S. In vitro evaluation of temozolomide combined with X-irradiation. AntiCancer Drugs 8 (1997) 92-97
17. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: phase I/II-study. J Clin Oncol 2004 [ASCO Annual Meeting Proceedings]; 22(14S):1531.
18. Chinot O.L., Honore S., Dufour H., et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19 (2001) 2449-2455
19. van den Bent M.J., Taphoom M.J., Brandes A.A., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for the research and treatment of cancer brain tumor group study 26971. J Clin Oncol 21 (2003) 2525-2528
20. Vogelbaum MA, Berkey B, Peereboom D, et al. RTOG 0131: phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. J Clin Oncol 2005 [ASCO Annual Meeting Proceedings]; 23(16S):1520.
21. Sasaki H., Zlatescu M.C., Betensky R.A., et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low grade "oligodendroglioma". J Neuropathol Exp Neurol 61 (2002) 58-63
22. Fuller C.E., Schmidt R.E., Roth K.A., et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid olidodendroglial/astrocytic features. J Neuropathol Exp Neurol 62 (2003) 1118-1128
23. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
24. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18 (2000) 636-645
25. Bauman G.S., Ino Y., Ueki K., et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48 (2000) 825-830
26. Chahlavi A., Kanner A., Peereboom D., Staugaitis S.M., Elson P., and Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61 (2003) 267-273
27. Ochs K., and Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and capase-9/3 regulated and Fas/capse-8 independent. Cancer Res 60 (2000) 5815-5824
28. Denny B.J., Wheelhouse R.T., Stevens M.F., Tsang L.L., and Slack J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33 (1994) 9045-9051
29. D'Atri S., Piccioni D., and Castellano A. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6 (1995) 389-393
30. Wedge S.R., Porteous J.K., and Newlands E.S. 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74 (1996) 1030-1036
31. Ludlum D.B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 233 (1990) 117-126
32. Pegg A.E., Wiest L., Foote R.S., Mitra S., and Perry W. Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J Biol Chem 258 (1983) 2327-2333
33. Pieper R.O. Understanding and manipulating O6-methylguanine-DNA methyltransferase expression. Pharmacol Ther 74 (1997) 285-297
34. Esteller M., and Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylgauanine DNA methyltransferase in human cancer. Oncogene 23 (2004) 1-8
35. Silber J.R., Blank A., Bobola M.S., Ghatan S., Kolstoe D.D., and Berger M.S. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5 (1999) 807-814
36. Jaeckle K.A., Eyre H.J., Townsend J.J., et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study. J Clin Oncol 16 (1998) 3310-3315
37. 6-methylguanine-DNA methyltransferase gene. Cancer Res 57 (1997) 3672-3677
38. Watts G.S., Pieper R.O., Costello J.F., Peng Y.M., Dalton W.S., and Futscher B.W. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17 (1997) 5612-5619
39. Estellar M., Hamilton S.R., Burger P.C., Baylin S.B., and Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 (1999) 793-797
40. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
41. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
42. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10 (2004) 4933-4938
43. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
44. Mollemann M., Wolter M., Felsberg J., Collins V.P., and Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113 (2005) 379-385
45. Laramore G.E., Martz K.L., Nelson J.S., Griffin T.W., Chang C.H., and Horton J. Radiation therapy oncology group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival?. Int J Radiat Oncol Biol Phys 17 (1989) 1351-1356
46. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 25 (2005) 1-7
47. Karran P., and Marinus M.G. Mismatch correction at O6-methylguanine residues in E. Coli DNA. Nature 296 (1982) 868-869
48. Liu L., Markowitz S., and Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56 (1996) 5375-5379
49. Roos W., Baumgartner M., and Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is medicated by p53 and Fas/CD95/Apo-1. Oncogene 23 (2004) 359-367
50. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16 (1998) 3851-3857
51. Rohn T.A., Wagenknecht B., Roth W., et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20 (2001) 4128-4137
52. Tentori L., Portarena I., Bonmassar E., and Graziani G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly(ADP-ribose)polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ 8 (2001) 457-469
53. Srivenugopal K.S., Shou J., Mullapudi S.R., Lang Jr. F.F., Rao J.S., and Ali-Osman F. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 7 (2001) 1398-1409
54. Tolcher A.W., Gerson S.L., Denis, et al. Marked inactivation of O6-alkylguanineDNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
55. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58 (1998) 4363-4367
56. Schold Jr. S.C., Kokkinakis D.M., Chang S.M., et al. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-oncology 6 (2004) 28-32
57. Dolan M.E., Stine L., Mitchell R.B., Moschel R.C., and Pegg A.E. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun 2 (1990) 371-377
58. Dolan M.E., and Pegg A.E. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3 (1997) 837-847
59. Wedge S.R., Porteus J.K., May B.L., and Newlands E.S. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer 73 (1996) 482-490
60. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18 (2000) 3522-3528
61. Quinn J.A., Pluda J., Dolan M.E., et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20 (2002) 2277-2283
62. Gerson S.L., Zborowska E., Norton K., Gordon N.H., and Willson J.K. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in human colon cancer xenografts completely resistant to BCNU alone. Biochem Pharmacol 45 (1993) 483-491
63. Dolan M.E., Pegg A.E., Biser N.D., Moschel R.C., and English H.F. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol 32 (1993) 221-225
64. Chinnasamy N., Rafferty J.A., Hickson I., et al. O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89 (1997) 1566-1573
65. McElhinney R.S., Donnelly D.J., McCormick J.E., et al. Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem 41 (1998) 5265-5271
66. Barvaux V.A., Lorigan P., Ranson M., et al. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther 3 (2004) 1215-1220
67. Tentori L., Portarena I., and Graziani G. Potential clinical applications of poly(ADP-ribose)polymerase (PARP) inhibitors. Pharmacol Res 45 (2002) 73-85
68. Curtin N.J., Wang L.-Z., Yiakouvaki A., et al. Novel poly(ADP-ribose)polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10 (2004) 881-889
69. Lapidus RG, Tentori L, Graziani G, et al. Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma n mice. J Clin Oncol 2005 [ASCO Annual Meeting Proceedings]; 23(16S):3136.
70. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose)polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (2004) 56-67
71. Plummer R, Middleton M, Wilson R, et al. First in human phase I trial of the PARP inhibitory AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol 2005 [ASCO Annual Meeting Proceedings]; 23(16S):3065.
72. Prados M.D., Seiferheld W., Sandler H.M., et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or withough BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. In J Radiat Oncol Biol Phys 58 (2004) 1147-1152
73. Donnelly E.T., Liu Y., Paul T.K., and Rockwell S. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay. Int J Radiat Oncol Biol Phys 62 (2005) 1176-1186
74. Miller R.A., Woodburn K.W., Fan Q., et al. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 7 (2001) 3215-3221
75. Magda D., Lepp C., Fan Q., Lecane P., and Miller R.A. The redox mediator motexafin gadolinium (MGd) enhances the activity of several chemotherapy drugs. Proc Am Soc Clin Oncol 22 (2003) 229
76. Ford J.M., Seiferheld W., Mehta M., Phan S., and Curran W. Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc Am Soc Clin Oncol 22 (2003) 106
77. Mehta M., Ford J.M., Suh J., and Phan S. Cumulative dose of motexafin gadolinium and survival in newly diagnosed glioblastoma multiforme. Neuro-oncology 6 (2004) 378
78. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
79. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
80. Prados M., Chang S., Burton E., et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Eur J Cancer Suppl 1 5 (2003) S14
81. Vogelbaum M.A., Peereboom D., Stevens G.H., Barnett G.H., and Brewer C. Phase II study of single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme. Ann Oncol 15 (2004) iii206
82. Uhm JH, Ballman KV, Giannini C, et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J Clin Oncol 2004 [ASCO Annual Meeting Proceedings]; 22(14S):1505.
83. Chakravarti A., Seiferheld W., Tu X., et al. Immunohistochemically determined total epidermal growth factor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 62 (2005) 318-327
84. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
85. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I (IGFRI) mediates resistance to anti-epidermal growth factor receptor (EGFR) therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 1 (2002) 200-207
86. Chakravarti A., Chakladar A., Delaney M.A., Latham D.E., and Loeffler J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62 15 (2002) 4307-4315
87. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
88. Chakravarti A, Seiferheld W, Robins HI, et al. An update of phase I data from RTOG 0211: a phase I/II clinical study of gefitinib + radiation for newly-diagnosed glioblastoma (GBM) patients. J Clin Oncol 2004 [ASCO Annual Meeting Proceedings]; 22(14S):1571.
89. Chakravarti A., Zhai G., Suzuki Y., et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22 10 (2004) 1926-1933
90. Conrad C, Friedman H, Reardon D, et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2004 [ASCO Annual Meeting Proceedings]; 22(14S):1512.
91. Dechantsreiter M.S., Planker E., Matha B., et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42 (1999) 3033-3040
92. Wilde-Bode C., Weller M., Rimner A., et al. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61 (2001) 2744-2750
93. Nabors L.B., Rosenfeld S.S., Mikkelsen T., et al. NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro-oncology 6 (2004) 379